The DOI matches its Crossref record; the references it cites are not checked yet.
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
Open accessAbstract
PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with immunofluorescence analysis, to uncover the immunogenomic determinants of the therapeutic response. Although conventional genomic markers (such as tumor mutation burden and neoantigen load) and the degree of CD8+ T cell infiltration were not associated with clinical response, we discovered numerous chromosomal alterations associated with response or resistance to PD-1 blockade. These advanced ccRCC tumors were highly CD8+ T cell infiltrated, with only 27% having a non-infiltrated phenotype. Our analysis revealed that infiltrated tumors are depleted of favorable PBRM1 mutations and enriched for unfavorable chromosomal losses of 9p21.3, as compared with non-infiltrated tumors, demonstrating how the potential interplay of immunophenotypes with somatic alterations impacts therapeutic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, low TMB does not preclude generation of effective antigen responses, nor does high TMB guarantee response to ICT (130-132).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 85 · Cited by 992
Metadata
- Authors
- Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., Steinharter, J., Sun, M., Wind-Rotolo, M., Pignon, J.-C., Cherniack, A. D., Lichtenstein, L., Neuberg, D., Catalano, P., Freeman, G. J., Sharpe, A. H., McDermott, D. F., Van Allen, E. M., Signoretti, S., Wu, C. J., Shukla, S. A., & Choueiri, T. K.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Wu, Catherine J.
- Shukla, Sachet A.
- Choueiri, Toni K.
- ORCID
- Braun, David A.
- Hou, Yue
- Bakouny, Ziad
- Ficial, Miriam
- Berger, Ashton C.
- Jegede, Opeyemi A.
- Sun, Maxine
- Pignon, Jean-Christophe
- Cherniack, Andrew D.
- Lichtenstein, Lee
- Neuberg, Donna
- Catalano, Paul
- Freeman, Gordon J.
- Sharpe, Arlene H.
- McDermott, David F.
- Van Allen, Eliezer M.
- Signoretti, Sabina
- Wu, Catherine J.
- Shukla, Sachet A.
- Choueiri, Toni K.
- Venue
- Nature Medicine
- Published
- 2020-05-29
- Volume
- 26
- Issue
- 6
- Pages
- 909-918
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7499153
- OpenAlex
- W3029490475
- Cited by
- 992
- References
- 85
- Citations by year
- 2026: 119 · 2025: 148 · 2024: 209 · 2023: 189 · 2022: 205 · 2021: 105 · 2020: 17
- FWCI
- 49.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA101942, R50CA211482, R01CA155010, T32CA009172, U24CA224331)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- clear cell renal cell carcinoma, anti-PD-1 therapy, immune checkpoint inhibitors, CD8+ T cell infiltration, somatic alterations, chromosomal abnormalities, PBRM1 mutation, tumor mutational burden, neoantigens, immunogenomics, treatment response, immunotherapy resistance
- MeSH terms
- Exome Sequencing, Antineoplastic Agents, Immunological, Tuberous Sclerosis Complex 1 Protein, Nivolumab, Adult, Aged, Aged, 80 and over, Histocompatibility Antigens Class II, Carcinoma, Renal Cell, Chromosome Deletion, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 9, DNA-Binding Proteins, Female, Fluorescent Antibody Technique, Humans, Kidney Neoplasms, Male, Middle Aged, Mutation, Prognosis, Histone-Lysine N-Methyltransferase, Transcription Factors, Lymphocytes, Tumor-Infiltrating, Gene Deletion, Sequence Analysis, RNA, Antigen Presentation, CD8-Positive T-Lymphocytes, Genomics, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Proteasome Endopeptidase Complex, PTEN Phosphohydrolase, Von Hippel-Lindau Tumor Suppressor Protein, Histone Demethylases, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41591-020-0839-y
- The paper
- Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., Steinharter, J., Sun, M., Wind-Rotolo, M., Pignon, J.-C., Cherniack, A. D., Lichtenstein, L., Neuberg, D., Catalano, P., Freeman, G. J., . . . Choueiri, T. K. (2020). Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-020-0839-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.